申请人:Anthrogenesis Corporation
公开号:EP2700309A1
公开(公告)日:2014-02-26
The present invention relates to collagenous membranes produced from amnion, herein referred to as a collagen biofabric. The collagen biofabric of the invention has the structural integrity of the native non-treated amniotic membrane, i.e., the native tertiary and quaternary structure. The present invention provides a method for preparing a collagen biofabric from a placental membrane, preferably a human placental membrane having a chorionic and amniotic membrane, by decellularizing the amniotic membrane. In a preferred embodiment, the amniotic membrane is completely decellularized. The collagen biofabric of the invention has numerous utilities in the medical and surgical field including for example, blood vessel repair, construction and replacement of a blood vessel, tendon and ligament replacement, wound-dressing, surgical grafts, ophthalmic uses, sutures, and others. The benefits of the biofabric are, in part, due to its physical properties such as biomechanical strength, flexibility, suturability, and low immunogenicity, particularly when derived from human placenta.
本发明涉及用羊膜生产的
胶原蛋白膜,在此称为
胶原蛋白生物布。本发明的
胶原蛋白生物织物具有未经处理的原生羊膜的结构完整性,即原生的三级和四级结构。本发明提供了一种用胎盘膜制备
胶原蛋白生物织物的方法,优选的胎盘膜是具有绒毛膜和羊膜的人类胎盘膜,制备方法是对羊膜进行脱细胞处理。在一个优选的实施方案中,羊膜是完全脱细胞的。本发明的
胶原蛋白生物布料在医疗和外科领域有许多用途,例如包括血管修复、血管的构建和替换、肌腱和韧带替换、伤口包扎、外科移植物、眼科用途、缝合等。
生物布料的优点部分是由于其物理特性,如
生物力学强度、柔韧性、可缝合性和低免疫原性,特别是当其来源于人类胎盘时。